Global Perspectives and Clinical Resources to Guide Treatment Decisions and Management of Adverse Events With BTK Inhibitor Therapy in CLL

Deepen your understanding of the optimal use of BTK inhibitors in CLL, including treatment strategies and managing potential AEs associated with these agents, through an expert-written text module with accompanying slides, a ClinicalThought commentary, and 2 interactive decision support tools—1 to support treatment decisions in CLL and another to support BTK inhibitor AE management.

Share

Program Content

Activities

CLL Treatment
My Thoughts on the Current and Emerging Treatment of CLL/SLL
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: October 25, 2024

Expires: October 24, 2025

Faculty

cover img faculity

Alessandra Tedeschi, MD

Consultant in Hematology
Division of Hematology
Niguarda Hospital
Milano, Italy

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC 

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca